Table 1 Study set and clinico-pathological features
From: Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples
Variable | Cases | Controls | P -value |
|---|---|---|---|
No. individuals | 239 | 239 | |
No. samples | 239 | 239 | |
Mean time to spin (h; range) | 24.05 (1.83–47.69) | 23.87 (1.77–47.78) | 0.52 |
Mean age at sample draw (years; range) | 61.24 (50.6–75.9) | 60.78 (50.3–76.5) | 0.3 |
Median time from sample draw to diagnosis (months; range) | 13.84 (0.13–53.81) | ||
Tumour grade (number of cases) | |||
1 | 47 | ||
2 | 111 | ||
3 | 81 | ||
Node status (number of cases) | |||
N0 | 176 | ||
N1 | 63 | ||
Stage (number of cases) | |||
1 | 115 | ||
2 | 87 | ||
3 | 12 | ||
4 | 2 | ||
Not assessed | 23 | ||
Metastasis (number of cases) | |||
M0 | 166 | ||
M1 | 2 | ||
Not assessed (Mx) | 28 | ||
Not available | 43 | ||
NPI estimate (number of cases) | |||
⩽4.0 | 107 | ||
>4.0 | 96 | ||
Not available | 36 | ||
HER2 status (number of cases) | |||
Negative | 136 | ||
Positive | 47 | ||
Not available | 56 | ||
ER status (number of cases) | |||
Negative | 47 | ||
Positive | 191 | ||
Unknown | 1 | ||
PR status (number of cases) | |||
Negative | 84 | ||
Positive | 132 | ||
Not available | 23 |
